Zealand Pharma (CPSE:ZEAL) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

ZEAL Panoramica delle azioni

Zealand Pharma A/S, società di biotecnologie, è impegnata nella scoperta, nello sviluppo e nella commercializzazione di farmaci a base di peptidi in Danimarca.

Informazioni sull'azienda

ZEAL analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 32.86% all'anno

Analisi del rischio

Prezzo delle azioni volatile negli ultimi 3 mesi

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Gli azionisti sono stati diluiti nell'ultimo anno

Zealand Pharma A/S Concorrenti

Genmab

CPSE:GMAB

DKK 115.6b

Bavarian Nordic

CPSE:BAVA

DKK 22.1b

BioPorto

CPSE:BIOPOR

DKK 919.5m

H. Lundbeck

CPSE:HLUN B

DKK 42.2b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Zealand Pharma
Prezzi storici delle azioni
Prezzo attuale dell'azione	DKK 874.00
Massimo di 52 settimane	DKK 972.00
Minimo di 52 settimane	DKK 252.60
Beta	0.64
1Variazione di 1 mese	-0.68%
Variazione a 3 mesi	44.94%
Variazione di 1 anno	225.63%
3Variazione a 3 anni	397.72%
Variazione a 5 anni	575.43%
Variazione dall'IPO	999.37%

Notizie e aggiornamenti recenti

Things Look Grim For Zealand Pharma A/S (CPH:ZEAL) After Today's Downgrade

Aug 21

Zealand Pharma A/S (CPH:ZEAL) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 18

Recent updates

Things Look Grim For Zealand Pharma A/S (CPH:ZEAL) After Today's Downgrade

Aug 21

Zealand Pharma A/S (CPH:ZEAL) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 18

Auditors Are Concerned About Zealand Pharma (CPH:ZEAL)

Mar 17

Here's Why We're Watching Zealand Pharma's (CPH:ZEAL) Cash Burn Situation

Oct 03

Downgrade: Here's How Analysts See Zealand Pharma A/S (CPH:ZEAL) Performing In The Near Term

Aug 14

Some Zealand Pharma A/S (CPH:ZEAL) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 14

Is Zealand Pharma's (CPH:ZEAL) 113% Share Price Increase Well Justified?

Mar 11

What You Need To Know About Zealand Pharma A/S' (CPH:ZEAL) Investor Composition

Jan 12

Rendimenti per gli azionisti

	ZEAL	DK Biotechs	DK Mercato
7D	-3.9%	2.5%	-0.3%
1Y	225.6%	3.9%	25.4%

Ritorno vs Industria: ZEAL ha superato il Danish Biotechs che ha restituito 8.2 % nell'ultimo anno.

Rendimento vs Mercato: ZEAL ha superato il mercato Danish che ha restituito 27.3 % nell'ultimo anno.

Volatilità dei prezzi

Is ZEAL's price volatile compared to industry and market?
ZEAL volatility
ZEAL Average Weekly Movement	8.9%
Biotechs Industry Average Movement	7.4%
Market Average Movement	4.3%
10% most volatile stocks in DK Market	9.1%
10% least volatile stocks in DK Market	2.8%

Prezzo delle azioni stabile: Il prezzo delle azioni di ZEAL è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 9% ) di ZEAL è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni Danish.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1997	288	Adam Steensberg	www.zealandpharma.com

Zealand Pharma A/S, società di biotecnologie, è impegnata nella scoperta, nello sviluppo e nella commercializzazione di farmaci a base di peptidi in Danimarca. Ha un portafoglio di farmaci incentrati su malattie gastrointestinali e metaboliche e su altre aree patologiche speciali con esigenze mediche insoddisfatte. L'azienda offre Dasiglucagon, una siringa o un autoiniettore monouso per il trattamento dell'ipoglicemia grave, e i sistemi di pancreas artificiale bi-ormone Dasiglucagon, contenenti insulina e dasiglucagone.

Zealand Pharma A/S Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Zealand Pharma con la sua capitalizzazione di mercato?
ZEAL statistiche fondamentali
Capitalizzazione di mercato	DKK 63.19b
Guadagni(TTM)	-DKK 712.00m
Ricavi(TTM)	DKK 367.97m

168.5x

Rapporto P/S

-87.1x

Rapporto P/E

ZEAL è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
ZEAL Conto economico (TTM)
Ricavi	DKK 367.97m
Costo del fatturato	DKK 714.45m
Profitto lordo	-DKK 346.47m
Altre spese	DKK 365.53m
Guadagni	-DKK 712.00m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

Nov 07, 2024

Utile per azione (EPS)	-10.04
Margine lordo	-94.16%
Margine di profitto netto	-193.49%
Rapporto debito/patrimonio netto	2.9%

Come si è comportato ZEAL nel lungo periodo?

Vedi performance storica e confronto

ZEAL Panoramica delle azioni

Premi

Analisi del rischio

Zealand Pharma A/S Concorrenti

CPSE:GMAB

DKK 115.6b

CPSE:BAVA

DKK 22.1b

CPSE:BIOPOR

DKK 919.5m

CPSE:HLUN B

DKK 42.2b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Things Look Grim For Zealand Pharma A/S (CPH:ZEAL) After Today's Downgrade

Zealand Pharma A/S (CPH:ZEAL) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 40%

Zealand Pharma A/S Appoints Eric Cox as Chief Commercial Officer, Effective August 5, 2024

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 6.257 billion.

Recent updates

Things Look Grim For Zealand Pharma A/S (CPH:ZEAL) After Today's Downgrade

Zealand Pharma A/S (CPH:ZEAL) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 40%

Zealand Pharma A/S Appoints Eric Cox as Chief Commercial Officer, Effective August 5, 2024

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 6.257 billion.

Zealand Pharma A/S Announces Positive Topline Results from the Phase 1B 16-Week Multiple Ascending Dose Clinical Trial with Long-Acting Amylin Analog Petrelintide

Zealand Pharma A/S Announces Boehringer Ingelheim Will Present Positive Results from Phase 2 Trial with Survivalodutide in MASH at EASL

Zealand Pharma Announces Topline Results from the Mechanistic Investigator-Led Dream Trial with Low Doses of GLP-1/GLP-2 Receptor Dual Agonist Dapiglutide

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated a Statistically Significant Improvement of Metabolic Dysfunction-Associated Steatohepatitis

Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S Appoints Enrique Conterno and Elaine Sullivan as Board Observers

Zealand Pharma A/S to Report Q1, 2024 Results on May 16, 2024

Boehringer Ingelheim and Zealand Pharma A/S Announces Initiation of Three Phase III Trials

Zealand Pharma A/S Announces Designation of Priority Review by the US FDA for Dasiglucagon in Congital Hyperinsulinism

Zealand Pharma A/S Announces Positive Results from Part 1 of Multiple Ascending Dosing Trial with Amylin Analog ZP8396

Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency

Boehringer Ingelheim and Zealand Pharma A/S Announces Phase II Trial Showed 14.9% Weight Loss in People Living with Obesity or Unveil

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 786.05 million.

Zealand Pharma A/S Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (Ease 1)

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism At the 60Th Annual Espe Meeting

Zealand Pharma A/S Announces Chief Financial Officer Changes

Zealand Pharma A/S Revises Revenue Guidance for the Full Year of 2022

Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the Nasdaq Global Select Market

Zealand Pharma A/S Presents Data from Phase 1 Trial of Dapiglutide and to Move into Phase 2 Trial for Obesity

Zealand Pharma Announces Appoints David M. Kendall, as Chief Medical Officer

Insufficient new directors

Consensus forecasts updated

Zealand Pharma A/S Announces Positive Top-Line Results from Its Second Phase 3 Clinical Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism

Zealand Pharma A/S (CPSE:ZEAL) entered into an agreement to acquire V-Go® Insulin Delivery Device from Zealand Pharma for $10 million.

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Price target decreased to kr.229

Zealand Pharma Announces CEO Changes

Auditors Are Concerned About Zealand Pharma (CPH:ZEAL)

Full year 2021 earnings: Revenues in line with analyst expectations

Consensus forecasts updated

Zealand Pharma A/S Announces Completion of Patient Enrollment in the Second Phase 3-Trial, 17103 in Children with Congenital Hyperinsulinism

Zealand Pharma Completes Enrollment in Ease-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Consensus forecasts updated

Zealand Pharma A/S announced that it expects to receive $200 million in funding from Oberland Capital Management LLC

Zealand Pharma Announces Successful Outcome of Phase 1B Clinical Trial with GLP1-GLP2 Dual Receptor Agonist, Dapiglutide

Price target decreased to kr.228

Third quarter 2021 earnings released: kr.4.61 loss per share (vs kr.5.76 loss in 3Q 2020)

Price target decreased to kr.236

Here's Why We're Watching Zealand Pharma's (CPH:ZEAL) Cash Burn Situation

Zealand Pharma A/S Presents Data At 2021 ESPEN Virtual Congress Demonstrating Dose-Dependent Effects of Glepaglutide in Both Small and Large Intestines of Animal Models –in Contrast to Short-Acting GLP-2

Employee Elected Director Gertrud Rasmussen has left the company

Employee Elected Director Gertrud Rasmussen has left the company

Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Downgrade: Here's How Analysts See Zealand Pharma A/S (CPH:ZEAL) Performing In The Near Term

Consensus EPS estimates fall to -kr.28.75

Protagonist Therapeutics, Inc Announces Resolution of Contract Dispute with Zealand Pharma

Zealand Pharma Announces U.S. Commercial Availability of Zegalogue (Dasiglucagon) Injection